Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Insulin Glargine is a long-acting human insulin analog that can control the patient's blood sugar more effectively and steadily. It is often used to treat type 1 and type 2 diabetes. Its original research manufacturer is Sanofi, and its trade name is Lantus, which came to the Chinese market in 2004. In 2020, in addition to the original research company, other manufacturers in the Chinese Insulin Glargine market are Gan&Lee Pharmaceuticals Co., Ltd. and Zhuhai United Laboratories Co., Ltd.
According to CRI's market research, the sales value of Insulin Glargine has shown an upward trend from 2016 to 2020 in China, reaching CNY960.49 million in 2020. Sales growth in 2020 has slowed down compared to previous years. The main reason is that the COVID-19 epidemic has impacted the hospital's overall diagnosis and treatment business. The CAGR of the sales value of Insulin Glargine in the Chinese market is 5.45% from 2016 to 2020.
Researcher predicts that from 2021 to 2025, the sales of Insulin Glargine in China will have a recovery growth with the improvement of the epidemic and the normal operation of the hospital's overall diagnosis and treatment business. In addition, its sales will also increase due to market expansion. The number of diabetic patients in China has ranked the first in the world, and there is a great demand for diabetes treatment drugs. Insulin Glargine belongs to the third generation of insulin. Compared with other types of insulin, third-generation insulin has greater advantages in terms of onset time, peak performance, and duration of action, indicating that the Insulin Glargine market has room for growth in China. In addition, the key patent of Insulin Glargine expired in 2015, and more generic drugs will appear in the Insulin Glargine market in the future. Therefore, the price of Insulin Glargine is expected to continue to fall, driving sales volume to increase sales.
Topics Covered:
-The impact of COVID-19 on China's Insulin Glargine market
- Sales value of China's Insulin Glargine 2016-2020
- Competitive landscape of China's Insulin Glargine market
- Prices of Insulin Glargine in China
- Prices of Insulin Glargine in China by regions and manufacturers
- Analysis on factors affecting the development of China's Insulin Glargine market
- Prospect of China's Insulin Glargine market from 2021 to 2025
According to CRI's market research, the sales value of Insulin Glargine has shown an upward trend from 2016 to 2020 in China, reaching CNY960.49 million in 2020. Sales growth in 2020 has slowed down compared to previous years. The main reason is that the COVID-19 epidemic has impacted the hospital's overall diagnosis and treatment business. The CAGR of the sales value of Insulin Glargine in the Chinese market is 5.45% from 2016 to 2020.
Researcher predicts that from 2021 to 2025, the sales of Insulin Glargine in China will have a recovery growth with the improvement of the epidemic and the normal operation of the hospital's overall diagnosis and treatment business. In addition, its sales will also increase due to market expansion. The number of diabetic patients in China has ranked the first in the world, and there is a great demand for diabetes treatment drugs. Insulin Glargine belongs to the third generation of insulin. Compared with other types of insulin, third-generation insulin has greater advantages in terms of onset time, peak performance, and duration of action, indicating that the Insulin Glargine market has room for growth in China. In addition, the key patent of Insulin Glargine expired in 2015, and more generic drugs will appear in the Insulin Glargine market in the future. Therefore, the price of Insulin Glargine is expected to continue to fall, driving sales volume to increase sales.
Topics Covered:
-The impact of COVID-19 on China's Insulin Glargine market
- Sales value of China's Insulin Glargine 2016-2020
- Competitive landscape of China's Insulin Glargine market
- Prices of Insulin Glargine in China
- Prices of Insulin Glargine in China by regions and manufacturers
- Analysis on factors affecting the development of China's Insulin Glargine market
- Prospect of China's Insulin Glargine market from 2021 to 2025
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
